Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Discover a study that examined the efficacy and safety of pemafibrate in 360 patients with MASLD and hypertriglyceridaemia.

The USDA’s Food Safety and Inspection Service (FSIS) and the FDA jointly have broad jurisdiction and oversight over the U.S.

While Applied Therapeutics has vowed to reapply or appeal the FDA’s recent rejection of its rare disease candidate govorestat ...

About one-third of US adults without diabetes who are eligible for weight loss treatment with GLP-1 receptor agonists and GLP-1/GIP receptor agonists meet exclusion criteria for clinical trials.

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

Are you confused by food label terms like “Sell By,” “Use By” and “Best By?” If so, you aren’t alone. Federal regulators ...

Marty Makary is a surgeon, prolific author, and avowed contrarian. He’s not a kook but is reckless with the facts, draws ...

As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...

Vocal patient advocates and researchers argue that certain drugs could help long COVID sufferers via off-label use. Some have ...